Wednesday, May 15, 2024 5/15/2024

Effectiveness of VBP15, a dissociative steroidal analogue, on chronic inflammation in a mouse model of multiple sclerosis

Award Number: R41AI122780
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By Issue Date FY or Funding FY:

View Award Abstract

¿ DESCRIPTION (provided by applicant): Glucocorticoids (GC's), such as prednisolone, are used frequently to induce remission and treat multiple sclerosis (MS). Despite effectiveness, many GC mediated detrimental side effects including osteoporosis and muscle atrophy limit long term chronic treatment of MS patients. These side effects are believed to be mediated by well described glucocorticoid response element (GRE) mediated transcriptional properties (transactivation), whereas efficacy is mediated by trans-repression of NFkB pro inflammatory pathways. ReveraGen BioPharma has identified a lead compound, VBP15, that is a novel dissociative steroid designed to maintain the anti-inflammatory efficacy of traditional steroids through NFkB inhibition and GR translocation, yet has lost GRE mediated transcriptional activities leading to much less side effects typically associated with traditional glucocorticoid drugs (no osteopenia, growth stunting, or steroid myopathy). Importantly, VBP15 has been shown to reduce inflammatory activity in vivo across multiple murine models of disease. Furthermore, we have demonstrated in a pilot study that VBP15 significantly reduces the severity of disease in the experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis (preliminary data). Thus, VBP15 may represent a safer and more effective alternative to traditional glucocorticoids in the treatment of MS. The goal of this STTR research is to extend preclinical evaluation of VBP15 by assessing the effect of treatment on disease in the mouse chronic relapsing remitting EAE model using published recommendations for pre-clinical studies. We hypothesize that VBP15 treatment after disease onset will result in similar anti-inflammatory activity compared to prednisolone but possess a much reduced side effect profile. As VBP15 has already entered Phase 1 clinical trials in adult healthy volunteers, transition to MS trials would likely ensure shortly after the successful completion of the proposed STTR grant.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2019 ( Subtotal = $0 )
2019	2016	REVERAGEN BIOPHARMA, INC.	155 GIBBS ST STE 433	ROCKVILLE	MD	20850	MONTGOMERY	USA	Allergy and Infectious Diseases Research	000	1	12/28/2018	NEW	$0
														Subtotal = $0

Issue Date FY: 2018 ( Subtotal = $0 )
2018	2016	REVERAGEN BIOPHARMA, INC.	155 GIBBS ST STE 433	ROCKVILLE	MD	20850	MONTGOMERY	USA	Allergy and Infectious Diseases Research	000	1	3/6/2018	NEW	$0
														Subtotal = $0

Issue Date FY: 2016 ( Subtotal = $253,802 )
2016	2016	VALIDUS BIOPHARMA INC	9700 GREAT SENECA HIGHWAY	ROCKVILLE	MD	20850	MONTGOMERY	USA	Allergy and Infectious Diseases Research	000	1	3/31/2016	NEW	$253,802
														Subtotal = $253,802

Grand Total All Awards = $253,802

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Effectiveness of VBP15, a dissociative steroidal analogue, on chronic inflammation in a mouse model of multiple sclerosis

Award Number: R41AI122780

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer